• News
  • SAN DIEGO
  • Finance

Analysts raise target for Neurocrine

Wall Street investment bank Leerink Partners on Tuesday raised its price target for San Diego’s Neurocrine Biosciences (Nasdaq: NBIX) from $18 to $23 per share after last month’s release of positive data on its proposed treatment for tardive dyskinesia, a disease characterized by involuntary muscle movements.

Leerink reiterated an "outperform" rating on the stock, which rose more than 3.5 percent by mid-morning in New York to around $16.77 per share.

In a column late last month, Motley Fool health care analyst Sean Williams said Neurocrine “should remain high on investors' watchlists” following the phase 2b study of NBI-98854, its proposed tardive dyskinesia treatment.

Williams said analysts estimate that if the drug is approved for the market, its sales could range between $500 million and $700 million.

“Given that the company is valued at roughly two times these estimates, some investors would perceive Neurocrine to be fully valued here,” he said. But he added that since Neurocrine currently has no competition in its niche, he believes that the current estimates may be a little low.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Subscribe Today!